Jeongwu Lee, PhD, Department of Cancer Biology, was awarded a five-year, $2.4 million grant from the National Cancer Institute, part of the National Institutes of Health, to study an FDA-approved drug to enhance treatment of glioblastoma (GBM), the most common and lethal form of brain cancer.
Dr. Lee and his team previously discovered that a dopamine receptor in the brain called DRD2 (dopamine receptor subtype 2) promotes the survival and growth of GBM cells, suggesting that it may be a good target for future pharmacological interventions. When DRD2 is “turned on,” it signals a chain of reactions that ultimately activates another receptor called c-MET (tyrosine-protein kinase Met). C-MET is known to regulate a dangerous subset of cancer cells called cancer stem cells and promote GBM therapeutic resistance.
The new grant will allow Dr. Lee to build on pre-clinical research related to ONC 201 (a recently developed DRD2 antagonist) and repurpose perphenazine, a clinically used anti-psychotic drug, as an anti-GBM treatment to determine if it can ultimately slow the growth and impede tumor recurrence. In additional to studying the cellular mechanisms at play, the team will look to preclinical models bearing patient-derived GBM tumors to better understand the effects of inhibiting DRD2 activity.
GBM tumors are extremely variable (on both genetic and cellular levels) from patient to patient, and it is particularly hard to deliver drugs into tumors due to the blood-brain-barrier (BBB). Dr. Lee is hopeful that this intervention will prove successful because early findings suggest the DRD2 inhibitor can in fact cross the BBB.
Associate Staff
Center for Cancer Stem Cell Research
Lab Profile
Dr. Bao’s group found that inhibiting DNA-PK overturns the pro-cancer properties of glioma stem cells and suppresses tumor growth in preclinical models, suggesting DNA-PK as a potential therapeutic target for treating glioblastoma.
Dr. Bao’s team found that WISP1, a key protein in the Wnt/β-catenin-WISP1 signaling pathway, contributes to glioblastoma progression by maintaining glioma stem cells and tumor-associated macrophages, and that blocking the pathway helped control the disease in preclinical models.
Dr. Bao’s team found that treating preclinical models of glioblastoma with verubecestat, a BACE1-inhibiting drug, reduces cancer progression by targeting a class of immune cells abundant in tumors.
The future of health starts with your support. Donations supply researchers with the tools, space and staff they need to think big.
Give to Cleveland Clinic